Living-Donor Lobar Lung Transplantation for Pulmonary Arterial Hypertension After Failure of Epoprostenol Therapy
Hiroshi Date, MD*,*,
Kengo Fukushima Kusano, MD ,
Hiromi Matsubara, MD,
Aiko Ogawa, MD,
Hideki Fujio, MD,
Katsumasa Miyaji, MD,
Megumi Okazaki, RN*,
Masaomi Yamane, MD*,
Shinichi Toyooka, MD*,
Motoi Aoe, MD*,
Yoshifumi Sano, MD*,
Motohiko Hanazaki, MD ,
Keiji Goto, MD,
Shingo Kasahara, MD ,
Shunji Sano, MD and
Tohru Ohe, MD
* Cancer and Thoracic Surgery
Cardiovascular Medicine
Anesthesiology and Resuscitology
Cardiovascular Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Kaplan-Meier Survival Curves in PAH Patients
Survival was assessed from the date of operation in patients receiving transplantation and from the date of acceptance as lung transplant candidates in patients treated medically. The survival was significantly better in patients receiving living-donor lobar lung transplantation (LDLLT) than in patients medically treated. p = 0.028, log-rank test. CLT = cadaveric lung transplantation; PAH = pulmonary arterial hypertension.
|
|
|
